RNA therapeutics
Eli Lilly Expands RNA Pipeline with $1.3 Billion Rznomics Hearing Loss Pact
Eli Lilly; Rznomics; RNA editing; hearing loss; gene therapy; pharmaceutical partnerships; biotech; trans-splicing ribozyme; sensorineural hearing loss; RNA therapeutics
Aptadir Therapeutics Unveils Novel RNA Inhibitors to Combat Cancer and Genetic Disorders
Aptadir Therapeutics, RNA inhibitors, DNMT1 interacting RNAs (DiRs), Cancer treatment, Genetic diseases, Epigenetic targeting, RNA therapeutics